Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children

Bone Marrow Transplantation

Volumn 41, Issue 6, 2008, Pages 571-577

  Inagaki, J ^a   Nagatoshi, Y ^a   Hatano, M ^a   Isomura, N ^a   Sakiyama, M ^a   Okamura, J ^a  

^a National Hospital Organization   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; MEPREDNISONE; METHOTREXATE; PREDNISONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; APLASTIC ANEMIA; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; WISKOTT ALDRICH SYNDROME;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PREDNISONE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 41549166180     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705922     Document Type: Article

References (37)

1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827-838.
2. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196-1201.
3. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
4. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB et al. A retrospectiye analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 1991; 77: 1821-1828.
5. Arai S, Margolis J, Zaburak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-160.
6. Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic disease. Clin Pharmacokinet 2003; 42: 139-151.
7. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110 353-356.
8. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132: 830-835.
9. Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: Indication for modulation of inflammatory mechanism. Rheumatol Int 1998; 18: 59-62.
10. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved toxicity. Semin Arthritis Rheum 1998; 27: 277-292.
11. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long DG et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225-1230.
12. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
13. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
14. Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Bherz DL et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-4389.
15. Giaccone L, Martin P, Carpenter P, Moravec C, Hooper H, Funke VAM et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36 337-341.
16. Huang XJ, Jiang Q, Chen H, Xu L, Liu D, Chen Y et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 343-348.
17. Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 1999; 11: 226-232.
18. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction, of interleukin-6, interferon-γ, and tumor necrosis factor-α in graft-versus-host disease. Bone Marrow Transplant 1994; 13: 745-751.
19. Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des 2004; 10: 1195-1205.
20. Ferrara JLM. Paradigm shift for graft-versus-host disease. Bone Marrow Transplant 1994; 14: 183-184.
21. Ferrara JLM, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3-10.
22. Przepiorka D, Weisdorf D, Martin P, Klingomann H-G, Beatty P, Hows J et al. 1994 Consensus, conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
23. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host disease syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
24. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
25. Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR, Ramsay NK et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: Failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77-82.
26. Khoury H, kashyap A, Adkins DR, Brown RA, Miller G, Vij R et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059-1064.
27. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001; 15: 147-153.
28. McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, Sutherland HJ et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367-374.
29. Couriel D, Saliba R, Hicks K, Ippoliti C, De Lima M, Hosing C et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
30. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant racipients: A cohort study. Blood 2003; 102: 2708-2776.
31. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35 1003-1010.
32. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005; 84: 681-685.
33. Bolanos-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23: 2661-2668.
34. Arora M, Burns LJ, Davies SM, MacMillan ML, Defor TE, Miller WJ et al. Chronic graft-versus-host disease: A prospective cohort study. Biol Blood Marrow Transplant 2003; 9: 38-45.
35. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S et al. Performance of a new clinical grading system for chronic graft-versus-host disease: A multicenter study. Blood 2003; 102 802-809.
36. Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 307-313.
37. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756-762.